Health economic evaluations: the special case of end-stage renal disease treatment.
about
Hypertension and hyperglycemia synergize to cause incipient renal tubular alterations resulting in increased NGAL urinary excretion in ratsTarget of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsTarget of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsThe cost-effectiveness of Vancouver's supervised injection facilityHow to overcome barriers and establish a successful home HD programClinician beliefs and attitudes about home haemodialysis: a multinational interview study.Ageism vs. the technical imperative, applying the GRADE framework to the evidence on hemodialysis in very elderly patientsExperimental Evaluation of Kidney Regeneration by Organ Scaffold RecellularizationWhen is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D studyKidney organ donation: developing family practice initiatives to reverse inertia.Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysisState medicaid coverage, ESRD incidence, and access to careCost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriersOptimal costs of HIV pre-exposure prophylaxis for men who have sex with menEgo mechanisms of defense are associated with patients' preference of treatment modality independent of psychological distress in end-stage renal diseaseAn epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease.Is surgery for displaced, midshaft clavicle fractures in adults cost-effective? Results based on a multicenter randomized, controlled trial.Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.High cost and low survival rate in high comorbidity incident elderly hemodialysis patientsThe pragmatist's guide to comparative effectiveness researchFirst- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.An economic assessment model for in-center, conventional home, and more frequent home hemodialysis.Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.Transplantation tolerance in pediatric recipients: lessons and challenges.The cost effectiveness of radiofrequency ablation for Barrett's esophagus.The Ethics of Chronic Dialysis for the Older Patient: Time to Reevaluate the Norms.Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study.Modality options for renal replacement therapy: the integrated care concept revisited.Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.Benefits Improvement and Protection Act's impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal diseaseMinimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Reimbursement and economic factors influencing dialysis modality choice around the world.The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada.Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.Probability, predictors, and prognosis of posttransplantation glomerulonephritisAn economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancerCost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis.
P2860
Q21558791-04D110C6-D4FD-4AE0-B18D-B1C93CD33D7EQ24187866-F945364E-BC29-4DE0-B934-AE8354C95EADQ24201591-235BF3AE-B87A-413E-9F50-9AD3CA49B7D3Q24657903-8B499884-ECD9-46F8-8291-F8169DA61A99Q30415883-85D35A15-6652-41B2-BAA7-B2A3D71965FCQ30530824-D59E7323-866C-46A4-B06D-5139AFCC02ABQ30541143-0F380A80-8622-424E-9911-4FEC7127395AQ30840855-537FFA63-616D-4D97-8166-CC7F766D7DE7Q33459789-0E401D16-69AA-4F41-8137-0D17D540D8D7Q33579573-52BF73AF-113D-4D1B-846C-69F96EC1E0AFQ33620490-7DE16D64-4005-4C49-A693-69C0E336B536Q33660593-BDF96DC7-3289-44A4-9D6F-3F5CFE8F5B24Q33679857-E0AC5895-E3EE-4AAB-A092-F99F57CBFCB6Q33751621-18007F4C-7174-4C8D-9E2F-4FE2AD200104Q33755727-FCDFA9DC-DB30-4060-BDFC-F0B39BA7FBAEQ33862914-A7CB6E97-CE58-4AF7-AD53-F28F79FBD352Q33943651-88377A32-F26A-4F4C-A7B3-8DE706B57CFBQ34073478-D40768BD-7D0E-442A-A110-B8DE21EDF0BBQ34990590-63A49552-503D-4153-9DCF-3792CE0B07C7Q35030741-8D2B69EB-FD2F-4CBA-9085-6A7D9EF7CD39Q35563197-C79F947C-8509-4A20-8B39-360677C06479Q35673540-F1B1A6B7-845A-4B5A-8921-03A407DF125FQ35743692-38F3EA43-528C-4F2E-975E-3C686DA48B10Q35754399-FE67D10D-175B-42FF-9214-7B5113938C3EQ36018578-BEE1C6C6-7C8D-4A76-B9AD-1C0E8800C28CQ36195501-1B42B479-4835-435E-B519-8AFEA7C038D3Q36250326-B02A7EFF-4C73-4EF9-89A8-01BBF2B6978CQ36322941-21CBCD20-BFEC-47BC-BCC0-ACD0C46DF034Q36453311-87AE0C50-6F72-48E6-999B-4172072698B8Q36553713-F11E19C1-09D9-46DD-ABEB-8AF013190B55Q36592263-DD795046-1D08-4199-8883-0270F0A2E39EQ36731638-9AEACD20-A4A2-4509-AE46-FEE0D193CF7AQ36740044-A3AD1295-1B29-43D4-9462-6F048E9E8811Q36742558-233A063D-43AC-481F-85B1-24DED581CC15Q37037308-AB59D9AA-F5A6-4806-8C11-288CF6569280Q37079386-E27045F7-1812-4BEA-AD4D-2FEA36C65CEFQ37146427-93471339-AB00-4FAB-84C6-9B6AE743D3D9Q37217323-70408EF1-D6B7-42BB-90B6-5C511187D685Q37367740-CE4B7377-40C8-4A2A-BC71-9F97053D522FQ37382232-BFEA3B37-18C7-4F1A-AD85-795A4B197230
P2860
Health economic evaluations: the special case of end-stage renal disease treatment.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Health economic evaluations: the special case of end-stage renal disease treatment.
@ast
Health economic evaluations: the special case of end-stage renal disease treatment.
@en
Health economic evaluations: the special case of end-stage renal disease treatment.
@nl
type
label
Health economic evaluations: the special case of end-stage renal disease treatment.
@ast
Health economic evaluations: the special case of end-stage renal disease treatment.
@en
Health economic evaluations: the special case of end-stage renal disease treatment.
@nl
prefLabel
Health economic evaluations: the special case of end-stage renal disease treatment.
@ast
Health economic evaluations: the special case of end-stage renal disease treatment.
@en
Health economic evaluations: the special case of end-stage renal disease treatment.
@nl
P2093
P1476
Health economic evaluations: the special case of end-stage renal disease treatment.
@en
P2093
Joseph S Pliskin
Murray A Mittleman
Robert J Glynn
Wolfgang C Winkelmayer
P304
P356
10.1177/027298902320556118
P577
2002-09-01T00:00:00Z